Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

NCT05797168 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05797168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05797168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 5, 2023
Completion date
August 4, 2028
Enrollment
622 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, lung adenocarcinoma, lung squamous cell carcinoma, ovarian cancer